Biogen's dispute with Italy hits Tysabri
This article was originally published in Scrip
A dispute with the Italian medicines agency AIFA has dragged on sales of the multiple sclerosis drug Tysabri (natalizumab) in the first half of this year, as revenues have had to be set aside pending the outcome of the argument. AIFA maintains that Biogen Idec, which is responsible for distribution of the product in Italy, has exceeded an agreed reimbursement limit, but the company counters that the agreement had expired.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.